Price Chart

Executive Summary

uniQure priced a $225M underwritten public offering of 4,945,055 ordinary shares at $45.50/share, a ~7.2% discount to the prior close of $49.04. Net proceeds of ~$211M will fund commercialization readiness, a confirmatory study for lead gene therapy AMT-130 (Huntington's disease), and pipeline development. The offering comes days after the company announced FDA alignment to accept Phase I/II data as the primary basis for a BLA submission under accelerated approval, a major regulatory de-risking event. The 7.8% dilution (4.95M new shares vs 63.0M outstanding) is a near-term overhang, but the capital raise removes a key financing overhang and funds the path to a pivotal BLA filing in Q3 2026.

Key Facts

• Offering of 4,945,055 ordinary shares at $45.50/share, raising ~$225M gross / ~$211M net proceeds
• Underwriters have a 30-day option to purchase up to an additional 741,758 shares
• Public offering price represents a ~7.2% discount to the June 23, 2026 close of $49.04
• Post-offering shares outstanding: 67,978,304 (68,720,062 if underwriters exercise option in full), a ~7.8% increase from 63,033,249
• Net proceeds of ~$211M will fund AMT-130 commercialization readiness, confirmatory study, pipeline development, and general corporate purposes
• On June 17, 2026, uniQure announced FDA alignment to accept Phase I/II data as primary basis for BLA under accelerated approval, with submission planned for Q3 2026
• Immediate dilution of $41.72 per share for new investors (public offering price of $45.50 vs. as-adjusted net tangible book value of $3.78)
• Lock-up agreements restrict insider sales for 60 days post-offering

Financial Impact

~$211M net capital infusion (~$242.7M if greenshoe exercised), representing ~6.8% of pre-offering market cap of $3.1B. Dilution of ~7.8% to existing shareholders.

Risk Factors

• Dilution of ~7.8% from new shares, with potential for further dilution if underwriters exercise greenshoe
• BLA submission and accelerated approval for AMT-130 remain subject to FDA alignment on confirmatory study design and acceptance of Phase I/II data
• Pre-revenue biotech with no approved products; commercialization and pipeline execution risk
• PFIC status risk for U.S. holders could create adverse tax consequences
• Stock volatility expected given limited trading volume and binary regulatory catalysts

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

US Market Status